A few simple changes can dramatically reduce endophthalmitis

Article

Changes to perioperative management of cataract patients, including the use of disposable bimanual irrigation/aspiration handpieces, intracameral cefuroxime and povidone iodine wash can be effective in reducing the instances of endophthalmitis.

Changes to perioperative management of cataract patients, including the use of disposable bimanual irrigation/aspiration handpieces, intracameral cefuroxime and povidone iodine wash can be effective in reducing the instances of endophthalmitis, according to Richard Packer from the King Edward VII Hospital, Windsor, UK.

These changes were made following a cluster of postoperative endophthalmitis cases (nine in a four-month period). Since the introduction of the new regimes in May 2004, a total of 7,584 eyes were operated on for cataract at the hospital's Prince Charles Eye Unit. Twenty-four different surgeons, including six consultants, three associate specialists and 15 trainees carried out the surgery.

One culture-negative endophthalmitis was recorded, this recovered after intravitreal antibiotics to achieve an uncorrected vision of 6/9 by three weeks postoperatively. This represents an incidence of just 0.013% which is well below that reported in the relevant literature.

Dr Packard concluded that it only takes the implementation of a few simple measures to dramatically reduce the incidence of postoperative endophthalmitis.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.